EI
NBSE

EAM Investors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

EAM Investors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-4,304
Closed -$756K – 368
2020
Q2 		$756K Sell
4,304
-897
-17% -$150K 0.17% 222
2020
Q1 		$741K Buy
5,201
+208
+4% +$27.5K 0.23% 176
2019
Q4 		$719K Buy
+4,993
New +$586K 0.16% 228
2014
Q2 		– Sell
-409
Closed -$2.23M – 377
2014
Q1 		$2.23M Buy
+409
New +$2.15M 0.4% 71

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

EAM Investors's NBSE Position: Q3 2020 in Review

EAM Investors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2020, closing a stake of 4,304 shares — an estimated $756K sold.

EAM Investors first reported a position in NBSE in Q1 2014 and held it in 4 quarters. The position peaked at $2.23M in Q1 2014. 50 funds tracked by Wall St. Rank hold NBSE as of Q3 2020.

  • EAM Investors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • EAM Investors sold 4,304 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $756K.
  • EAM Investors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 4 quarters.
  • EAM Investors's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.23M in Q1 2014.
  • 50 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2020.

Based on EAM Investors's 13F filing for Q3 2020, filed 13 Nov 2020.